Tech Company Financing Transactions
KetoSwiss Funding Round
On 8/8/2023, KetoSwiss announced $4.8 million in funding from private investors.
Transaction Overview
Company Name
Announced On
8/8/2023
Transaction Type
Venture Equity
Amount
$4,800,000
Round
Undisclosed
Investors
Proceeds Purpose
The company will use the funds to drive development of migraine fighting food. The company has also expressed its plans 'to extend its portfolio to other neurological diseases characterised by metabolic dysfunction, such as Alzheimer's Disease' in the future.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Picassopl. 4
Basel, 4052
CH
Basel, 4052
CH
Phone
Undisclosed
Website
Email Address
Overview
KetoSwiss is a Swiss biotechnology start-up that develops "brain fuels" as 1) nutraceuticals (/supplements) and 2) pharmaceuticals for the therapy of migraine ("MigraKet"), which are efficacious and close to the root cause of migraine, without adding intolerable side effects. Our lead product's active substance is an endogenous metabolite -- a ketone body, which can be used by the brain as an alternative fuel to glucose when glucose utilization or transport is compromised. In later stages of development, our portfolio can be extended to other neurological diseases characterized by metabolic dysfunction, such as Alzheimer's Disease (AD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elena Gross
Chief Financial Officer
Sebastian Hersberger
Browse more venture capital transactions:
Prev: 8/8/2023: Puffer Finance venture capital transaction
Next: 8/8/2023: FishBrain venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs